Athenex’s clinical pipeline includes small molecule, biologic, and cell therapies for the treatment of cancer.
| Modality | Candidate | Target / Combination | Indication | Pre-clinical | Phase I | Phase II/Pivotal | Stage | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cell Therapy Platform | ||||||||||||||
| Autologous CAR-NKT | KUR-501 | GD2 | R/R High Risk Neuroblastoma | GINAKIT2 | Phase I — GINAKIT2 | |||||||||
| Allogeneic CAR-NKT | KUR-502 | CD19 | R/R Lymphoma and Leukemia | ANCHOR | Phase I | |||||||||
| Allogeneic CAR-NKT | KUR-503 | GPC3 | Advanced HCC | Pre-clinical | ||||||||||
| Allogeneic TCR-NKT | p53, KRAS, EGFR driver mutations | Genetically Driven Epithelial Cancers | Pre-clinical | |||||||||||
| Orascovery Platform | ||||||||||||||
| Oral Chemotherapy | Oral paclitaxel + encequidar | dostarlimab | Neoadjuvant Breast Cancer | I-SPY 2 | Phase II — I-SPY 2 | |||||||||
| Oral Chemotherapy | Oral paclitaxel + encequidar | pembrolizumab | Solid Tumors | KX-ORAX-011 | Phase I — KX-ORAX-011 | |||||||||
